262 related articles for article (PubMed ID: 28669130)
41. Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up.
Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
Transpl Immunol; 2017 Feb; 40():42-50. PubMed ID: 27888093
[TBL] [Abstract][Full Text] [Related]
42. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
[TBL] [Abstract][Full Text] [Related]
43. Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction.
Hurst FP; Altieri M; Nee R; Agodoa LY; Abbott KC; Jindal RM
Am J Nephrol; 2011; 34(6):534-41. PubMed ID: 22104284
[TBL] [Abstract][Full Text] [Related]
44. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
45. Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience.
Florescu DF; Seaman JA; Kalil AC; Qiu F; Bremers D; Westphal SG
Transplant Proc; 2021 Apr; 53(3):1058-1063. PubMed ID: 32921434
[TBL] [Abstract][Full Text] [Related]
46. Eight-year follow-up in pediatric living donor kidney recipients receiving alemtuzumab induction.
Kaabak MM; Babenko NN; Shapiro R; Maschan AA; Zokoev AK; Schekaturov SV; Vyunkova JN; Dymova OV
Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28600850
[TBL] [Abstract][Full Text] [Related]
47. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
[TBL] [Abstract][Full Text] [Related]
48. Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens.
Aydin-Ghormoz E; Ortiz J; Koizumi N; Li MH; Faddoul G
Pediatr Transplant; 2024 Jun; 28(4):e14783. PubMed ID: 38767019
[TBL] [Abstract][Full Text] [Related]
49. Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis.
Li KHC; Ho JCS; Recaldin B; Gong M; Ho J; Li G; Liu T; Wu WKK; Wong MCS; Xia Y; Dong M; Tse G;
Transplant Proc; 2018 Dec; 50(10):3723-3731. PubMed ID: 30577263
[TBL] [Abstract][Full Text] [Related]
50. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
[TBL] [Abstract][Full Text] [Related]
51. Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review.
Zhang X; Huang H; Han S; Fu S; Wang L
Transpl Immunol; 2012 Oct; 27(2-3):63-8. PubMed ID: 22960043
[TBL] [Abstract][Full Text] [Related]
52. Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation.
Alloway RR; Woodle ES; Abramowicz D; Segev DL; Castan R; Ilsley JN; Jeschke K; Somerville KT; Brennan DC
Am J Transplant; 2019 Aug; 19(8):2252-2261. PubMed ID: 30838775
[TBL] [Abstract][Full Text] [Related]
53. Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.
Sparkes T; Ravichandran B; Opara O; Ugarte R; Drachenberg CB; Philosophe B; Bromberg JS; Barth RN
Clin Transplant; 2019 Jun; 33(6):e13531. PubMed ID: 30866104
[TBL] [Abstract][Full Text] [Related]
54. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Watson CJ; Bradley JA; Friend PJ; Firth J; Taylor CJ; Bradley JR; Smith KG; Thiru S; Jamieson NV; Hale G; Waldmann H; Calne R
Am J Transplant; 2005 Jun; 5(6):1347-53. PubMed ID: 15888040
[TBL] [Abstract][Full Text] [Related]
55. Alemtuzumab Induction Is Associated With Equalization of Graft Outcomes Between Elderly and Nonelderly Kidney Transplant Recipients: A Single-Center Report.
DeLeonibus A; Mitro G; Brooks J; Rees M; Ortiz J
Exp Clin Transplant; 2020 Jun; 18(3):284-291. PubMed ID: 31050614
[TBL] [Abstract][Full Text] [Related]
56. Basiliximab: a review of its use as induction therapy in renal transplantation.
McKeage K; McCormack PL
BioDrugs; 2010 Feb; 24(1):55-76. PubMed ID: 20055533
[TBL] [Abstract][Full Text] [Related]
57. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
58. Effects of induction therapy with alemtuzumab versus antithymocyte globulin among highly sensitized kidney transplant candidates.
Shamsaeefar A; Roozbeh J; Khajerezae S; Nikeghbalian S; Kazemi K; Motazedian N; Geramizadeh B; Malekhosseini SA
Saudi J Kidney Dis Transpl; 2016; 27(4):665-70. PubMed ID: 27424681
[TBL] [Abstract][Full Text] [Related]
59. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
[TBL] [Abstract][Full Text] [Related]
60. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
Kaufman DB; Leventhal JR; Gallon LG; Parker MA
Am J Transplant; 2006 Feb; 6(2):331-9. PubMed ID: 16426317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
